| Literature DB >> 31569367 |
Adriana C S Pais1, Jorge A Saraiva2, Sílvia M Rocha3, Armando J D Silvestre1, Sónia A O Santos4.
Abstract
Marine resources are considered as a very promising source of bioactive molecules, and macroalgae in particular have gained special attention, due to their structurally diverse composition. Particular interest has been devoted to the brown macroalga Bifurcaria bifurcata, due to their abundance in bioactive linear diterpenes. In this appraisal, a thorough review concerning the methodologies used in the extraction, fractionation, and identification of diterpenes from B. bifurcata is provided and discussed in detail. An exhaustive compilation of the mass spectra and nuclear magnetic resonance (NMR) data are also provided. The in vitro and in chemico assays already performed to assess different biological activities attributed to B. bifurcata diterpenes are also reviewed, emphasizing the use of isolated components, enriched fractions, or crude extracts. The associated major strengths and challenges for the exploitation of B. bifurcata diterpenes for high-value applications are critically discussed.Entities:
Keywords: Bifurcaria bifurcata; biological activities; extraction; high value applications; identification; linear diterpenes; macroalgae
Mesh:
Substances:
Year: 2019 PMID: 31569367 PMCID: PMC6835738 DOI: 10.3390/md17100556
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Distribution, in percentage, of the studies on B. bifurcata linear diterpenes and/or on related biological activities, according to the sampling location. The percentages presented in this graphic were determined considering the number of samples of each geographical location in all published studies here reviewed. (Analyzing Institute for Scientific Information (ISI) Web of Knowledge, keywords: Bifurcaria bifurcata, diterpenes; timespan: 1980–2019).
Figure 2Chemical structures of acyclic diterpenes identified in B. bifurcata, belonging to family A.
Figure 3Chemical structures of acyclic diterpenes identified in B. bifurcata, belonging to family B1.
Figure 4Chemical structures of acyclic diterpenes identified in B. bifurcata, belonging to subfamily B2.
Figure 5Chemical structures of acyclic diterpenes identified in B. bifurcata, belonging to family C.
Linear diterpenes extracted from B. bifurcata, and the respective pretreatment, extraction, purification/fractionation and identification/analysis methodologies used, and time of collection/geographical origin.
| Extraction Methodology | EY a | Sample Pretreatment | Fractionation/Purification | Identification/Analysis | Compound (Content b) | Time of Collection/Geographical. Origin | Ref |
|---|---|---|---|---|---|---|---|
| EtOAc S–L extraction | 1.70 | Freeze-dried | Chromatography (on Silica gel) eluted with EtOAc- | (1H and 13C) NMR, MS | July to August/Roscoff, Brittany, France | [ | |
| EtOAc S–L extraction | N.D. | Freeze-dried | LC using Silica gel with a solvent gradient from DCM to DCM-MeOH (80:20); | HRESIMS, 1D and 2D NMR |
| September/Roscoff, Brittany, France | [ |
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
| EtOAc S–L extraction, at RT | 4.80 | Freeze-dried and ground | Successive flash and CC (on Silica gel), eluting with cyclohexane—EtOAc mixture; | HREIMS, (1H and 13C) NMR | November to September/Basse-Normandie, France | [ | |
| EtOAc S–L extraction, at RT | N.D. | Freeze-dried and ground | Flash chromatography eluting with a H2O-MeOH mixture of increasing polarity (95:5–0:100 in 30 minutes) | 2D NMR, HPLC-DAD-MS-SPE-NMR |
| June/Cap Lévi, English Channel, France | [ |
| EtOAc S–L extraction, at RT | 4.8 | Freeze-dried and ground | CC (on Silica gel) eluted with a solvent gradient from DCM to DCM-MeOH (80:20) | (1H and 13C) NMR, HRESI(+)MS | September/Roscoff, Brittany, France | [ | |
| CHCl3 S–L extraction | N.D. | Normal and reverse phase flash CC and RP18 HPLC | 1D and 2D NMR, HRMS |
| May/Kilkee, County Clare of Ireland | [ | |
|
| |||||||
| CHCl3-EtOH S–L extraction | 1.52 | Freeze-dried and ground | Partitioning between H2O and Et2O; | IR, (1H and 13C) NMR, EIMS | -/Atlantic coast Morocco | [ | |
| CHCl3-MeOH S–L extraction, at RT | 5.53 | Shade-dried and ground | Partitioning in the mixture MeOH-isooctane (1:1); | HREIMS, (1H and 13C) NMR | December/Oualidia, Morocco | [ | |
| CHCl3- MeOH S–L extraction; | 1.95 g ext | Freshly collected | Open CC (on Silica gel) eluted with hexane to EtOAc (2:3); | IR, UV, (1H and 13C) NMR, EIMS, HRMS | -/Morocco | [ | |
| CHCl3-MeOH S–L extraction | 2.63 | Shade-dried | Partitioning in the mixture MeOH-isooctane (1:1); | HRMS, IR, (1H and 13C) NMR |
| -/Oualidia, Morocco | [ |
|
| |||||||
| CHCl3-MeOH S–L extraction, at RT | 6.92 | Air-dried and ground | MeOH extract: defatting with | HPLC |
| July/Quiberon, Brittany, France | [ |
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
|
| |||||||
| CHCl3- MeOH S–L extraction, at RT | 3.11 | Shade-dried and ground | CC (on Silica gel) eluted with a solvent gradient from cyclohexane to EtOAc and then from EtOAc to MeOH; | HREIMS, IR, (1H and 13C) NMR | July/Quiberon, Brittany, France | [ | |
| Et2O S–L extraction, at RT | 1.65 | Freeze-dried and powder | Partitioning between H2O and Et2O; | HRMS, EIMS, IR, (1H and 13C) NMR | January to December/Atlantic coast of Morocco | [ | |
| Et2O S–L extraction | 2.94 | Air-dried and ground | CC (on Silica gel) eluted with a gradient from isooctane to EtOAc; | 1D and 2D NMR | November/Oualidia, Morocco | [ | |
| 3.15 | December/Quiberon, Brittany, France | ||||||
| Et2O S–L extraction, at RT | 2.94 | Shade-dried and ground | CC (on Silica gel) eluted with a solvent gradient from isooctane to EtOAc | HRMS, (1H and 13C) NMR | December/Oualidia, Morocco | [ | |
| Et2O S–L extraction | N.D. | Freeze-dried | Preparative HPLC (DCM-EtOAc, 90:10) | UV, IR, (1H and 13C) NMR, MS | -/Loire-Atlantique, France | [ | |
| Et2O S–L extraction | N.D. | Shade-dried | Separation in different fractions |
| -/Brittany, France | [ | |
|
| |||||||
| Et2O S–L extraction, at RT, for 48h | 2.2-2.9 | Air-dried and ground | CC (on Silica gel) eluted with a solvent gradient from isooctane to EtOAc; | IR, UV, HRMS, 1D and 2D NMR | July to June/Roscoff, Brittany, France | [ | |
| Et2O S–L extraction, at RT | 2.40 | Freeze-dried and ground | Partitioning between H2O and Et2O; | HRMS, EIMS, IR, (1H and 13C) NMR | July to August/Roscoff, Brittany, France | [ | |
| Et2O S–L extraction, at RT | 3.15 | Shade-dried and ground | CC (on Silica gel) eluted with a solvent gradient from isooctane to EtOAc; | HRMS, EIMS, IR, (1H and 13C) NMR. | December/Quiberon and Roscoff, Brittany, France | [ | |
| 2.40 | CC (on Silica gel) eluted with a solvent gradient from hexane to Et2O; | ||||||
| Et2O S–L extraction | N.D. | Dried | LC using Silica gel; | IR, MS, NMR |
| -/Quiberon, Brittany, France | [ |
|
| |||||||
|
| |||||||
| Et2O S–L extraction, at RT | N.D. | Crushed and freeze-dried | Insoluble impurities and pigments elimination with isooctane and EtOH-H2O, respectively; | UV, IR, (1H and 13C) NMR, MS | -/Loire-Atlantique, France | [ | |
| Et2O S–L extraction (3x) (3h at 20ºC) | 3.67 | Freeze-dried and powder | CC (on Silica gel) eluted with a solvent gradient from hexane to Et2O | IR, UV, MS, (1H and 13C) NMR |
| January to December/Piriac, France | [ |
| Et2O S–L extraction | N.D. | Dried | LC using Silica gel; | IR, MS, NMR | -/El Jadida, Morocco | [ | |
| DCM S–L extraction, at RT; | 9.06 | Freeze-dried | Modified Kupchan method: partitioning between (90:10) MeOH-H2O and | IR, 1D and 2D NMR, HRMS, VCD | May/Kilkee, County Clare of Ireland | [ | |
| MeOH S–L extraction | 0.95 | Freeze-dried | VLC (on Silica gel) eluted with cyclohexane-EtOAc (1:2); | (1H, 13C, APT, COSY, HMBC and HSQC) NMR | May to June/Peniche, Portugal | [ | |
| DCM Soxhlet extraction (9 h) | 3.92 | Freeze-dried and ground | GC-MS | May/Ria de Aveiro, Portugal | [ | ||
a—% (w/w); b—when available, % of dw; 1H—proton; 13C—carbon; 1D and 2D—one and two dimensional; APT—attached proton test; CC—column chromatography; COSY—correlated spectroscopy; DAD—diode array detector; DCM—dichloromethane; EIMS—electron ionization mass spectrometry; ELSD—evaporative light scattering detector; ESI—electrospray ionization; Et2O—diethyl ether; EtOAc—ethyl acetate; EtOH—ethanol; EY—extraction yield; ext.—extract; fr.—fraction; HMBC—heteronuclear multiple bond correlation; HPLC—high performance liquid chromatography; HRMS—high resolution mass spectrometry; HSQC—heteronuclear single quantum coherence; IR—infrared spectroscopy; LC—liquid chromatography; L–L—liquid–liquid; MeCN—acetonitrile; MeOH—methanol; MS—mass spectrometry; N.D.—nondeterminate; NMR—nuclear magnetic resonance; PTLC—plate thin layer chromatography; Ref—reference; RI—refractive index detector; rt—retention time; RP—reverse phase; RT—room temperature; S–L—solid–liquid; SPE—solid phase extraction; TLC—thin-layer chromatography; UV—ultraviolet spectroscopy; VCD—vibrational circular dichroism; VLC—Vacuum liquid chromatography.
B. bifurcata linear diterpenes and crude extracts’ biological activities.
| Compounds/Crude Extract (Yield) | Biological Activities | Ref. |
|---|---|---|
| 12-( | Antimitotic activity (assay of cytotoxicity activity—inhibition of development of fertilized eggs of the common sea urchin | [ |
| Antifouling activity toward macroalgae spore and zygote development ( | [ | |
| ( | Antimitotic activity (assay of cytotoxicity activity—inhibition of development of fertilized eggs of the common sea urchin | [ |
| (2 | Cytotoxic activity: inhibit in vitro proliferation of pathogenic cells (NSCLC-N6—derived from a human non–small-cell bronchopulmonary carcinoma) by terminal differentiation. IC50 = 12.3 μg mL−1 | [ |
| (2 | Cytotoxic activity: inhibit in vitro proliferation of pathogenic cells (NSCLC-N6—derived from a human non–small-cell bronchopulmonary carcinoma) by terminal differentiation. IC50 = 9.5 μg mL−1 | [ |
| Eleganediol ( | Antibacterial activity (against | [ |
| Antifouling activity toward macroalgal spore and zygote development ( | ||
| Antimitotic activity (assay of cytotoxicity activity—inhibition of development of fertilized eggs of the common sea urchin | [ | |
| Antiadhesion activity (against a strain of | [ | |
| Antifouling activity (against | [ | |
| Toxicity (against | ||
| Antiproliferative activity toward MDA-MB-231 tumor cells (1.8% cell viability at 100 μg mL−1) | [ | |
| Bifurcane ( | Antimitotic activity (assay of cytotoxicity activity - inhibition of development of fertilized eggs of the common sea urchin | [ |
| Antiproliferative activity toward MDA-MB-231 tumor cells (2.9% cell viability at 100 μg mL−1) | [ | |
| Bifurcatriol ( | Antimalarial activity (against resistant K1 strain of the malaria parasite, | [ |
| Antiprotozoal activity: | ||
| Cytotoxicity against the L6 rat myoblast cell line (IC50 = 56.6 ± 0.004 μg mL−1) | ||
| Eleganolone ( | Antimicrobial activity (against | [ |
| Antiprotozoal activity (against | [ | |
| In vitro antiplasmodial activity (against | [ | |
| Antibacterial activity (against | [ | |
| Anti-adhesion activity (against a strain of | [ | |
| Antifouling activity (against | [ | |
| Toxicity (against | ||
| Cytotoxicity (against mouse fibroblast cell line (L929), IC50 = 22 μg mL−1) | [ | |
| Antioxidant potential (ORAC—1663.83 ± 25.35 µmol TE g−1 of compound, FRAP—8341.18 ± 177.72 µM FeSO4 g−1 compound) | [ | |
| (6 | Cytotoxicity (against mouse fibroblast cell line (L929), IC50 = 18 μg mL−1) | [ |
| (10 | Antimicrobial activity against gram-positive bacteria ( | [ |
| Eleganolal (23) | Antioxidant potential (ORAC—667.48 ± 10.96 µmol TE g−1 of compound, FRAP—8635.37 ± 389.54 µM FeSO4 g−1 compound) | [ |
| (6 | Antimicrobial activity against gram-positive bacteria ( | [ |
| Eleganolonebutenolide (32) | Cytotoxicity (against mouse fibroblast cell line (L929), IC50 = 27 μg mL−1) | [ |
| 14,15-dihydro-eleganonic acid (33) | Cytotoxicity (against mouse fibroblast cell line (L929), IC50 = 20 μg mL−1) | [ |
| Geranylgeraniol (39) | Antifouling activity—macroalgal spore and zygote development ( | [ |
| Bifurcanol (41) | Antimitotic activity (assay of cytotoxicity activity—inhibition of development of fertilized eggs of the common sea urchin | [ |
| Cytotoxicity (against mouse fibroblast cell line (L929), IC50 = 24 μg mL−1). | [ | |
| DCM extract (3.92 ± 0.09% (w/w)) | Antioxidant activity (in vitro | [ |
| Anti-inflammatory activity (NO production (% of LPS): 6% at 50 μg mL−1) | ||
| Antibacterial activity (against both gram-positive ( | ||
| Synergistic effects with antibiotic:Against | ||
| EtOAc extract * | Antiprotozoal activity (against erythrocytes infected by a resistant K1 strain of | [ |
| Cytotoxicity activity (against L6 cells, rat skeletal myoblasts, IC50 = 6 μg mL−1) | ||
| EtOAc:MeOH (1:1) soluble extract* | Anti-tubercular activity (against | [ |
| Antiprotozoal activity (against | ||
| Cytotoxicity (IC50 = 32.7 μg mL−1) | ||
| DCM-MeOH ASE extract* | Antioxidant activity (DPPH assay: EC50 = 0.56 ± 0.00 mg mL−1, reducing activity: 90.97% at 500 mg L−1, | [ |
| Antitumoral activity (tested with Daudi (Human Burkitt’s lymphoma), K562 (Human chronic myelogenous leukemia) (~40% of viable cells), and Jurkat (Human leukemic T cell lymphoblast) (~20% of viable cells) cells) | ||
| MeOH clean and enrich extract * | Antioxidant activity (TPC: 129.17 ± 0.002 mg GAE g−1 ext, ORAC: 3151.35 ± 119.33 μmol TE g−1 ext, DPPH: IC50 = 58.82 (50.65 − 68.31) μg mL−1) | [ |
| Antimicrobial activity (against | ||
| Antitumor activity: cell proliferation inhibition (tested in 2 in vitro carcinoma models, a human colorectal adeno-carcinoma (Caco-2) (IC50 = 437.1 (266.0 − 718.1) μg mL−1), and a human hepatocellular liver cancer (HepG-2) (IC50 = 252.0 (162.0 − 392.2) μg mL−1)) | ||
| DCM extract * | Antioxidant activity (TPC: 43.21 ± 0.043 mg GAE g−1 ext, ORAC: 589.98 ± 7.33 μmol TE g−1 ext, DPPH: IC50 = 344.70 (246.10 − 482.80) μg mL−1) | [ |
| Antimicrobial activity (against gram-negative bacteria ( | ||
| Antitumor activity: cell proliferation inhibition and cytotoxicity (tested in 2 in vitro carcinoma models, a human colorectal adeno-carcinoma (Caco-2) (IC50 = 82.31 (54.7 − 123.8) μg mL−1) (IC50 = 90.09 (70.82 − 114.6) μg mL−1), and a human hepatocellular liver cancer (HepG-2) (IC50 = 95.63 (69.66 − 131.3) μg mL−1) (IC50 = 123.9 (95.47 − 160.8) μg mL−1)) | ||
| Et2O extract(2.2%–2.9% of dw) | Antifouling activity (against 2 marine bacteria, | [ |
| MeOH clean and enriched extract(6.92% of dw) | Anti-proliferative effect (of well-differentiated pathologic cells, such as a human non–small-cell bronchopulmonary carcinoma line (NSCLC-N6) (IC50 = 4 μg mL−1), by terminal differentiation) | [ |
| EtOAc extract(4.80% of dw) | Antiprotozoal activity (against | [ |
| Et2O extract | Antifouling activity (against | [ |
| Toxicity (against | ||
| Et2O extract(3.15% of dw) | Antifouling activity toward macroalgal spore and zygote development ( | [ |
| Fraction of DCM extract(0.95% of dw) | Neuroprotective effect (prevent changes in mitochondrial potential (218.10% ± 14.87% of control), reduction of H2O2 levels production (204.50% ± 15.12% of control), revert neurotoxic effect on cell viability to about 20%–25%). | [ |
ABTS - 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid; ASE—accelerated solvent extraction; DCM—dichloromethane; DPPH—2,2-diphenyl-1-picrylhydrazyl assay; EC50—efficient concentration of extract to decrease microbial concentration by 50%; Ext—extract; FRAP—ferric reducing antioxidant power; Gent—gentamicin; GI—growth inhibition; IC50—inhibitory concentration of the extract required to decrease microbial concentration by 50%; LC—lethal concentration; LPS—lipopolysaccharides; MIC—minimal inhibitory concentration; ORAC—oxygen radical absorbent capacity; Rif—rifampicin; SI—selectivity index; TE—trolox equivalents; Tetra—tetracycline; TPC—total phenolic content; ZI—zone of inhibition; *—linear diterpenes were not identified, however the authors justify theoretically that these components may be responsible for the determined biological activities.